Literature DB >> 32980840

Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology.

Miriam Cellini1, Emilia Biamonte1, Massimiliano Mazza1, Nicoletta Trenti2, Pasquala Ragucci2, Davide Milani3, Emanuele Ferrante4, Zefferino Rossini3, Elisabetta Lavezzi1, Elisa Sala4, Giovanna Mantovani4,5, Maura Arosio4,5, Maurizio Fornari3, Luca Balzarini2, Andrea G Lania6,7, Gherardo Mazziotti1,8.   

Abstract

INTRODUCTION: Acromegaly is commonly complicated by arthropathy and skeletal fragility with high risk of vertebral fractures (VFs).
OBJECTIVE: This study aimed to assess whether VFs may be associated with sagittal spine deformities, arthropathy, impaired quality of life (QoL), pain, and disability.
METHODS: Thirty-eight patients with acromegaly (median age: 55 years, 20 males) and 38 matched control subjects were evaluated by a low-dose sagittal and coronal planes, X-ray imaging system (EOS®-2D/3D) for morphometric VFs, radiological signs of spine arthropathy, and spine deformities (Cobb thoracic index ≥40°, pelvic incidence minus lumbar lordosis ≥10°, pelvic tilt >20°, and sagittal vertical axis ≥4 cm) determining sagittal spine imbalance. Acromegalic patients were also evaluated by questionnaires for QoL (Acromegaly QoL Questionnaire [AcroQoL] and Short Form-36 [SF-36]) and pain and disability (Western Ontario and McMaster University [WOMAC]).
RESULTS: Acromegalic patients showed higher prevalence of thoracic hyperkyphosis (i.e., Cobb thoracic index ≥40°; p = 0.04) and pelvic tilt >20° (p = 0.02) than control subjects. VFs were found in 34.2% of acromegalic patients (p = 0.003 vs. control subjects), in relationship with higher prevalence of hyperkyphosis (p = 0.03), pelvic tilt >20° (p = 0.04), sagittal vertical axis ≥4 cm (p = 0.03), and moderate/severe subchondral degeneration (p = 0.01). Moreover, patients with VFs had lower AcroQoL general health (p = 0.007) and SF-36 general health (p = 0.002) scores and higher WOMAC pain (p = 0.003) and global (p = 0.009) scores than patients who did not fracture.
CONCLUSIONS: In acromegaly, VFs may be associated with spine deformities and sagittal imbalance, spine arthropathy, impaired QoL, and disability.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Acromegaly; Fractures; Kyphosis; Osteoporosis; Spine imbalance

Mesh:

Year:  2020        PMID: 32980840     DOI: 10.1159/000511811

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  5 in total

1.  Direct effects of octreotide on osteoblast cell proliferation and function.

Authors:  E Vitali; E Palagano; M L Schiavone; G Mantovani; C Sobacchi; G Mazziotti; A Lania
Journal:  J Endocrinol Invest       Date:  2022-01-12       Impact factor: 4.256

Review 2.  Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.

Authors:  Gherardo Mazziotti; Andrea G Lania; Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2022-03-14       Impact factor: 43.330

3.  Artificial intelligence-based radiomics on computed tomography of lumbar spine in subjects with fragility vertebral fractures.

Authors:  E Biamonte; R Levi; F Carrone; W Vena; A Brunetti; M Battaglia; F Garoli; G Savini; M Riva; A Ortolina; M Tomei; G Angelotti; M E Laino; V Savevski; M Mollura; M Fornari; R Barbieri; A G Lania; M Grimaldi; L S Politi; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2022-06-25       Impact factor: 5.467

4.  Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.

Authors:  Sabrina Chiloiro; Antonella Giampietro; Irene Gagliardi; Marta Bondanelli; Miriam Veleno; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis; Antonio Bianchi
Journal:  Pituitary       Date:  2022-08-03       Impact factor: 3.599

Review 5.  Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.

Authors:  P Maffei; F Dassie; S Camerini; A Wennberg; M Adriani; B Martin; R Vettor
Journal:  J Endocrinol Invest       Date:  2022-03-23       Impact factor: 5.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.